Emibetuzumab Reference: HY-P99192 Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
oYo-Link® MNase Antibody Labeling Kit - Labels 100ug Reference: AT6001-100 oYo-Link® MNase allows for the site-specific labeling of All oYo-Link®-compatible antibodies with Micrococcal nuclease (MNase). MNase is derived from Staphylococcus aureus and is a relatively non-specific endonuclease that is capable of digesting single-stranded, double-stranded, circular and linear nucleic acids (DNA and RNA). MNase is widely used to study chromatin structure in chromatin immunoprecipitation (ChIP) assays by preferentially digesting naked DNA between nucleosomes and thus enriching the nucleosome- protected DNA fragments. The resulting undigested DNA is subjected to high-throughput sequencing and mapped to a reference genome. These assays can sometimes benefit from the direct conjugation of MNase to antibodies that target a desired transcription factor. Direct conjugation can also allow for epigenetic mapping within just a small number of cells, since the MNase can be directed to specific transcription factors or chromatin-associated proteins. One such approach is called the CUT&RUN Assay, whereby DNA is digested directly in cells using protein A (pA)-MNase or protein G (pG)-MNase conjugates. Since oYo-Link® MNase allows for the site-specific and covalent attachment of MNase directly to any antibody of choice, it can simplify in cell digestion assays by eliminating time-consuming incubation and wash-steps. It also prevents release of MNase. This can result in higher yield and higher resolution maps of genome-wide epigenetic changes. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For additional questions concerning compatibility email support@alphathera.com
Omalizumab Reference: HY-P9950 Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
oYo-Link® MNase Antibody Labeling Kit - Labels 500ug Reference: AT6001-500 oYo-Link® MNase allows for the site-specific labeling of All oYo-Link®-compatible antibodies with Micrococcal nuclease (MNase). MNase is derived from Staphylococcus aureus and is a relatively non-specific endonuclease that is capable of digesting single-stranded, double-stranded, circular and linear nucleic acids (DNA and RNA). MNase is widely used to study chromatin structure in chromatin immunoprecipitation (ChIP) assays by preferentially digesting naked DNA between nucleosomes and thus enriching the nucleosome- protected DNA fragments. The resulting undigested DNA is subjected to high-throughput sequencing and mapped to a reference genome. These assays can sometimes benefit from the direct conjugation of MNase to antibodies that target a desired transcription factor. Direct conjugation can also allow for epigenetic mapping within just a small number of cells, since the MNase can be directed to specific transcription factors or chromatin-associated proteins. One such approach is called the CUT&RUN Assay, whereby DNA is digested directly in cells using protein A (pA)-MNase or protein G (pG)-MNase conjugates. Since oYo-Link® MNase allows for the site-specific and covalent attachment of MNase directly to any antibody of choice, it can simplify in cell digestion assays by eliminating time-consuming incubation and wash-steps. It also prevents release of MNase. This can result in higher yield and higher resolution maps of genome-wide epigenetic changes. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For additional questions concerning compatibility email support@alphathera.com
Palivizumab Reference: HY-P9944 Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
oYo-Link® MNase Antibody Labeling Kit - Labels 1mg Reference: AT6001-1000 oYo-Link® MNase allows for the site-specific labeling of All oYo-Link®-compatible antibodies with Micrococcal nuclease (MNase). MNase is derived from Staphylococcus aureus and is a relatively non-specific endonuclease that is capable of digesting single-stranded, double-stranded, circular and linear nucleic acids (DNA and RNA). MNase is widely used to study chromatin structure in chromatin immunoprecipitation (ChIP) assays by preferentially digesting naked DNA between nucleosomes and thus enriching the nucleosome- protected DNA fragments. The resulting undigested DNA is subjected to high-throughput sequencing and mapped to a reference genome. These assays can sometimes benefit from the direct conjugation of MNase to antibodies that target a desired transcription factor. Direct conjugation can also allow for epigenetic mapping within just a small number of cells, since the MNase can be directed to specific transcription factors or chromatin-associated proteins. One such approach is called the CUT&RUN Assay, whereby DNA is digested directly in cells using protein A (pA)-MNase or protein G (pG)-MNase conjugates. Since oYo-Link® MNase allows for the site-specific and covalent attachment of MNase directly to any antibody of choice, it can simplify in cell digestion assays by eliminating time-consuming incubation and wash-steps. It also prevents release of MNase. This can result in higher yield and higher resolution maps of genome-wide epigenetic changes. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For additional questions concerning compatibility email support@alphathera.com
Sontuzumab Reference: HY-P99591 Sontuzumab (AS1402) is a humanised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 100ug Reference: AT7001-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Briquilimab Reference: HY-P99488 Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID).
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug Reference: AT7001-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Enfortumab Reference: HY-P99016 Enfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 1mg Reference: AT7001-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com